MENU

Julia Judd, DO

This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Clinical Instructor, Department of Hematology/Oncology

Thoracic Oncology Program

Key Awards

The NIH Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32), Fox Chase Cancer Center, July 2020-June 2022   
 
The Fox Chase Cancer Center Young Investigator Award, July 2021-June 2022       

 

Treatment Philosophy

I believe in treating the patient as a whole.  This includes offering cutting edge treatment strategies for their disease but also focusing on the psychological and social needs of the person with the disease.  I strive to offer the best treatment possible by working with my colleagues from the fields of medical, radiation and surgical oncology who also focus on lung cancer treatment.  The benefit of being treated at an academic center like Fox Chase is access to innovative treatment strategies being tested on clinical trials, which allows us to offer therapies prior to their FDA approval.  I spend the time to educate my patients and their families, to the extent my patients are comfortable, on their disease and the potential treatment options.  I want all of my patients to feel empowered to be active participants in their care, and work with me to decide on the best, personalized, treatment plan.

Education and Training

Educational Background

  • 2018-2021 Hematology/Oncology Fellowship, Fox Chase Cancer Center/Temple University Hospital, Philadelphia, PA
  • 2015-2018 Internal Medicine Residency, Temple University Hospital, Philadelphia, PA
  • 2011-2015 DO, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
  • 2007-2011 BS, Biology, Chemistry minor, University of Pittsburgh, Pittsburgh, PA

    Certifications

    • American Board of Internal Medicine

    Memberships

    • American Medical Association
    • American Osteopathic Association
    • American College of Physicians
    • American Society of Clinical Oncology
    • American Society of Hematology
    • International Association for the Study of Lung Cancer (IASLC) 
    Publications

    Selected Publications

    Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR, Al-Saleem TI. Low level of blood CD4+ T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia 2017; 17 (2): 83 – 88.

    Judd J, Zibelman MR, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). The Oncologist 2017; 22 (10): 1232-1237.

    Judd J, Borghaei H. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer. Review. Thoracic Surgery Clinics 2020, Volume 30 (2): 199 – 206.

    Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski M, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Spira AI, Korn WM, Kim ES, Liu SV, and Borghaei H. Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics 2021. Accepted pending publication.

    Additional Publications

    Judd, J. Physician-patient communication and the use of over-the-counter medication and supplements by patients with gynecologic cancer undergoing chemotherapy. Oral presentation. Society of Gynecologic Oncology, Hot Springs, VA, October 2009

    Judd, J. Physician-patient communication and the use of over-the-counter medication and supplements by patients with gynecologic cancer undergoing chemotherapy. Poster presentation. Society of Gynecologic Oncology, San Francisco, CA, March 2010

    Al-Saleem TI, Dulaimi E, Millenson MM, Smith MR, Judd J, Li T, Borghaei H. Low blood absolute CD4 counts is associated with inferior progression free survival in diffuse large B-cell lymphoma independent of age and IPI. Blood, December 2014, 124 (21) 5420

    Judd J, Zibelman MR, Handorf E, O'Neill J, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). Poster presentation. American Society of Clinical Oncology, Chicago, IL, June 2016

    Zibelman MR, Judd J, Handorf E, O’Neill J, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Association of eosinophilia with efficacy in non-melanoma patients treated with programmed death 1 inhibitors. Poster presentation. American Society of Clinical Oncology, Chicago, IL, June 2016.

    Judd J, Ramamurthy C, Handorf E, Borghaei H, Geynisman DM, Zibelman M, Bauman J. Response and Adverse Events to Chemotherapy After Prior Checkpoint Inhibition in Lung Cancer. Poster presentation. American Society of Clinical Oncology – Society for Immunotherapy of Cancer Symposium, San Francisco, CA, January 2018.

    Liu SV, Vanderwalde AM, Mamdani H, Raez LE, Baca Y, Xiu J, Wolfgang MK, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Chul K, Antoinette WJ, Chukwuemeka I, Lopes G, Spira AI, Judd J, Kim E, Borghaei H. Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC). Poster presentation. American Society of Clinical Oncology, June 2020.

    Judd J, Handorf E, Gupta B, Edelman MJ. Analysis of first-line treatment (tx) patterns in advanced non-small cell lung cancer (NSCLC) patients (pts) with compromised performance status (PS), organ dysfunction (dfxn) or other significant comorbidities. Online Publication. American Society of Clinical Oncology, June 2021.

    Naqash AR, Floudas CS, Maoz A, Xiu J, Baca Y, Zeng J, Kim C, Judd J, Nieva J, Borghaei H, Takebe N, Liu SV, Mamdani H. Influence of TP53 co-mutation on the tumor microenvironment (TME) in STK11-mt Non-Small Cell Lung Cancer (NSCLC). Poster Presentation. American Society of Clinical Oncology, June 2021.

    MyNCBI

    Connect with Fox Chase